Stroke Prevention in NVAF: Optimizing Screening and Management

Significant challenges remain to improving stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) despite recent advances in therapeutic management options. Often asymptomatic and increasing in prevalence, the consequences of undiagnosed and untreated atrial fibrillation are dire—leaving patients at increased risk for ischemic stroke. This case-based activity addresses the challenges of improving patient care for NVAF, focusing on implementation of guideline-directed screening approaches in a real-world setting, individualized stroke risk stratification, and holistic therapeutic management strategies using thromboprophylaxis with oral anticoagulants for stroke prevention.
Gerald V. Naccarelli, MD

Text Module

Significant challenges remain to improving stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) despite recent advances in therapeutic management options. Often asymptomatic and increasing in prevalence, the consequences of undiagnosed and untreated atrial fibrillation are dire—leaving patients at increased risk for ischemic stroke. This case-based activity addresses the challenges of improving patient care for NVAF, focusing on implementation of guideline-directed screening approaches in a real-world setting, individualized stroke risk stratification, and holistic therapeutic management strategies using thromboprophylaxis with oral anticoagulants for stroke prevention.

Gerald V. Naccarelli, MD Released: July 8, 2019
Provided by Continuing Education Alliance

For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com

Supported by an educational grant from
Bristol-Myers Squibb
Pfizer Alliance

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue